Last reviewed · How we verify
NNC0174-0833
At a glance
| Generic name | NNC0174-0833 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity (PHASE1)
- A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body (PHASE1)
- Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) (PHASE2)
- A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants (PHASE1)
- Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. (PHASE2)
- A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity (PHASE1)
- Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant (PHASE1)
- A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NNC0174-0833 CI brief — competitive landscape report
- NNC0174-0833 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI